Format

Send to

Choose Destination
Clin Obstet Gynecol. 2018 Sep;61(3):544-561. doi: 10.1097/GRF.0000000000000365.

Pharmacotherapy for Perinatal Depression.

Author information

1
Departments of Psychiatry, Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai.
2
Department of Psychiatry, New York University School of Medicine.
3
Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
4
Department of Psychiatry, Icahn Medical School at Mount Sinai, New York.

Abstract

Perinatal depression is associated with serious risks for the mother, baby, and family. When considering treating perinatal depression with a drug indicated for the treatment of depression, the major concerns are whether the drug increases the risks of teratogenicity, pregnancy complications, poor neonatal adaptation, or neurodevelopmental disorders. Although different studies have produced different results, the majority have not shown increases in risk for selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, or the noradrenergic/dopaminergic drug bupropion. In this review we will discuss the reproductive safety data for these medications as well as monoamine oxidase inhibitors and benzodiazepines.

PMID:
29561284
DOI:
10.1097/GRF.0000000000000365
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center